gamida cell

INSPIRED TO CURE

COMPANY HIGHLIGHTS

Clinical-stage company with potential for first product launch in 2021

Worldwide rights to pipeline built on innovative cell-expansion platform

Management team with deep experience in cell therapy, clinical development and commercialization

MANAGEMENT TEAM

Julian Adams, Ph.D.
Chief Executive Officer

Josh Hamermesh
Chief Business Officer

Thomas Klima
Chief Commercial Officer

Shai Lankry
Chief Financial Officer

Tracey Lodie, Ph.D.
Chief Scientific Officer

Tzvi Palash
Chief Operating Officer

Tony Peled
Co-Founder and Chief Technology Officer

Ronit Simantov, M.D.
Chief Medical Officer

ABOUT GAMIDA CELL

We are an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our novel cell-expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.

Our cell therapies have the potential to significantly improve patient outcomes.

We are advancing omidubicel, which is in Phase 3 development as a potential life-saving treatment option for patients in need of bone marrow transplant. Our pipeline also includes GDA-201, an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies.

TECHNOLOGY PLATFORM

Our cell-expansion platform is designed to enhance the number and functionality of donor cells, enabling us to create potentially transformative therapies that move beyond what is possible with existing approaches.

Leveraging the unique properties of nicotinamide, we are able to expand multiple cell types — including stem cells and natural killer cells — with appropriate growth factors to maintain the cells' original phenotype and potency.

This potentially allows us to administer a therapeutic dose of cells that may improve patient outcomes.

Omidubicel and GDA-201 are investigational therapies, and their safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority. For more information on clinical trials, please visit www.clinicaltrials.gov.

PROGRAMS

Our team is working to develop potentially curative advanced cell therapies for blood cancers and serious blood diseases, including high-risk leukemias, lymphomas and severe aplastic anemia.

We are expanding what's possible in cell therapy for these diseases with our two wholly owned cell therapies.

Omidubicel

Omidubicel, our lead clinical program, is a cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with blood cancers. Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU.

Data from a Phase 1/2 clinical study demonstrated that treatment with omidubicel:

- Was generally well-tolerated.
- Resulted in rapid and durable time to engraftment, in which donor cells begin producing healthy cells.
- Reduced median time to engraftment by **50 percent** compared to a historical evaluation of patients who received standard umbilical cord blood.[1]

A Phase 3 study evaluating omidubicel in patients with leukemia and lymphoma is ongoing in the U.S., Europe, Asia and South America.[2] Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia, a rare and life-threatening blood disorder.[3]

GDA-201

GDA-201 is an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. When combined with targeted antibodies, GDA-201 has shown enhanced antibody-dependent cellular toxicity, or ADCC.

GDA-201 is in Phase 1 development in patients with refractory non-Hodgkin lymphoma and multiple myeloma.[4]

Omidubicel and GDA-201 are investigational therapies, and their safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority. For more information on clinical trials, please visit www.clinicaltrials.gov.

REFERENCES

1. Horwitz M.E., Wease S., Blackwell B., Valcarcel D. et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. *J Clin Oncol.* 2019 Feb 10;37(5):367-374.
2. ClinicalTrials.gov identifier NCT02730299.
3. ClinicalTrials.gov identifier NCT03173937.
4. ClinicalTrials.gov identifier NCT03019666.

PIPELINE



FOLLOW US ON SOCIAL MEDIA

@GamidaCellTx

Gamida Cell LTD

INVESTOR RELATIONS CONTACT

Jaren Irene Madden, Gamida Cell Ltd.

Email: IRPR@gamida-cell.com

MEDIA CONTACT

Max Stendahl, Ten Bridge Communications

Email: max@tenbridgecommunications.com